Among immunotherapeutic agents, recombinant interleukin-15 (IL-15) is particularly promising due to its potent stimulation of natural killer (NK) cells and CD8 + T cells, which are crucial for anti-tumor immunity (10). This evidence concerns the gene IL15 and neoplasm.